novartis_window

Novartis’ ligelizumab tops Xolair in chronic spontaneous urticaria

pharmafile | January 9, 2020 | News story | Research and Development Novartis, Xolair, ligelizumab 

Novartis has provided a burst of new data directly comparing its therapy ligelizumab with the current standard of care Xolair (omalizumab), also manufactured by the company, in the treatment of the skin condition chronic spontaneous urticaria (CSU).

The firm revealed that a new study determined that ligelizumab is more effective at inhibiting the major pathogenic IgE/FcεRI pathway in CSU compared to Xolair, binding to IgE in a different manner and with an 88-fold higher affinity.

“This mechanistic research study is a great step forward in understanding how different anti-IgE treatments can have qualitatively and functionally distinct inhibition profiles”, explained Dr Alexander Eggel of the University of Bern, Switzerland, and an investigator on the study.

“We were recently encouraged by previous clinical study results showing more patients are completely symptom-free from CSU with ligelizumab than Xolair,” added Eric Hughes, Global Development Unit Head for Immunology, Hepatology and Dermatology at Novartis. “This mechanistic study further supports those findings as we look to reimagine care to bring better treatment options for patients with CSU.”

Advertisement

Matt Fellows

Related Content

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

Mosquito image

First malaria medicine for infants under 4.5kg receives approval

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …

The Gateway to Local Adoption Series

Latest content